Baseline clinical characteristics, antiretroviral therapy use, and viral load suppression among HIV-positive young men of color who have sex with men

AIDS Patient Care and STDs

Volumn 25, Issue SUPPL. 1, 2011, Pages

  Hightow Weidman, Lisa B ^a   Jones, Karen ^b   Phillips, Gregory ^b   Wohl, Amy ^c   Giordano, Thomas P ^d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

^c Los Angeles County Department of Public Health   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR;

ADULT; AFRICAN AMERICAN; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL FEATURE; COHORT ANALYSIS; DISEASE COURSE; DRUG USE; HEALTH CARE UTILIZATION; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MALE HOMOSEXUAL; MINORITY GROUP; VIRUS LOAD;

ADOLESCENT; AFRICAN AMERICANS; ANTI-HIV AGENTS; COHORT STUDIES; HISPANIC AMERICANS; HIV INFECTIONS; HOMOSEXUALITY, MALE; HUMANS; MALE; UNITED STATES; VIRAL LOAD; YOUNG ADULT;

EID: 84860413506     PISSN: 10872914     EISSN: 15577449     Source Type: Journal    
DOI: 10.1089/apc.2011.9881     Document Type: Article

References (35)

1. Fleming PL, Byers RH, Sweeney PA, Daniels D, Karon JM, Janssen RS. HIV Prevalence in the United States. Oral abstract, session 5, presentation 11, 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 24-28, 2002.
2. Rotheram-Borus MJ. Annotation: HIV prevention challenges. Realistic strategies and early detection programs. Am J Public Health 1997;87:544-546.
3. Valdiserri RO, Holtgrave DR, West GR. Promoting early HIV diagnosis and entry into care. AIDS 1999;13:2317-2330.
4. Giordano TP, Gifford AL, White AC, Jr., et al. Retention in care: A challenge to survival with HIV infection. Clin Infect Dis 2007;44:1493-1499.
5. Berg MB, Safren SA, Mimiaga MJ, Grasso C, Boswell S, Mayer KH. Nonadherence to medical appointments is associated with increased plasma HIV RNA and decreased CD4 cell counts in a community-based HIV primary care clinic. AIDS Care 2005;17:902-907.
6. Naar-King S, Bradford J, Coleman S, Green-Jones M, Cabral H, Tobias C. Retention in care of persons newly diagnosed with HIV: Outcomes of the Outreach Initiative. AIDS Patient Care STDS 2007;21:S40-48.
7. Ashman JJ,ConviserR, PoundsMB.Associations betweenHIVpositive individuals' receipt of ancillary services and medical care receipt and retention. AIDS Care 2002;14:S109-118.
8. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: Analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006;41:194-200.
9. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003;362:22-29.
10. Munakata J, Benner JS, Becker S, Dezii CM, Hazard EH, Tierce JC. Clinical and economic outcomes of nonadherence to highly active antiretroviral therapy in patients with human immunodeficiency virus. Med Care 2006;44:893-899.
11. Sullivan P, Kayitenkore K. Reduction of HIV transmission risk and high risk sex while pPrescribed ART: Results from Discordant Couples in Rwanda and Zambia. Paper presented at: 16th Conference on Retrovirus and Opportunistic Infections, 2009; Montreal, Canada.
12. Ribera E, Paradineiro JC, Curran A, et al. Improvements in subcutaneous fat, lipid profile, and parameters of mitochondrial toxicity in patients with peripheral lipoatrophy when stavudine is switched to tenofovir (LIPOTEST study). HIV Clin Trials 2008;9:407-417.
13. Levine AJ, Hinkin CH, Castellon SA, et al. Variations in patterns of highly active antiretroviral therapy (HAART) adherence. AIDS Behav 2005;9:355-362.
14. Lazo M, Gange SJ, Wilson TE, et al. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: Longitudinal study of men and women. Clin Infect Dis 15 2007;45:1377-1385.
15. Horberg M, Silverberg M, Hurley L, Delorenze G, Quesenberry C. Influence of prior antiretroviral experience on adherence and responses to new highly active antiretroviral therapy regimens. AIDS Patient Care STDS 2008;22:301-312.
16. Magnus M, Jones K, Phillips G, et al. Characteristics associated with retention among African American and Latino adolescent HIV-positive men: Results from the Outreach, Care, and Prevention to Engage HIV-Seropositive Young MSM of Color Special Project of National Significance Initiative. J Acquir Immune Defic Syndr 2010;53:529-536.
17. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV- 1-infected adults and adolescents. Department of Health and Human Services. December 1, 2009. Available at: http:// www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL pdf. Accessed December 21, 2009.
18. Radloff LS. The CES-D scale: A self-report depression scale in the general population. Appl Psych Meas 1977;1:385-401.
19. DHHS. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2009. Available at: http://www.aidsinfo.nih.gov/ guidelines/, accessed on December 1, 2009.
20. Teshale EH, Kamimoto L, Harris N, Li J, Wang H, McKenna M. Estimated number of HIV-infected persons eligible for and receiving HIV antiretroviral therapy, 2003-United States, CROI 2005; February 22-25; Abstract No. 167.
21. Bogart LM, Kelly JA, Catz SL, Sosman JM. Impact of medical and nonmedical factors on physician decision making for HIV/AIDS antiretroviral treatment. J Acquir Immune Defic Syndr 2000;23:396-404.
22. Robison LS, Westfall AO, Mugavero MJ, et al. Short-term discontinuation of HAART regimens more common in vulnerable patient populations. AIDS Res Hum Retroviruses 2008;24:1347-1355.
23. Applebaum AJ, Richardson MA, Brady SM, Brief DJ, Keane TM. Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance- related disorder. AIDS Behav 2009;13:60-65.
24. Norman LR, Basso M, Kumar A, Malow R. Neuropsychological consequences of HIV and substance abuse: A literature review and implications for treatment and future research. Curr Drug Abuse Rev 2009;2:143-156.
25. Hendershot CS, Stoner SA, Pantalone DW, Simoni JM. Alcohol use and antiretroviral adherence: Review and metaanalysis. J Acquir Immune Defic Syndr 2009;52:180-202.
26. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-1826.
27. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ countguided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-2296.
28. Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: A systematic overview. J Acquir Immune Defic Syndr 2006;41:323-331.
29. Weintrob AC, Grandits GA, Agan BK, et al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr 2009;52:574-580.
30. Hartzell JD, Spooner K, Howard R, Wegner S, Wortmann G. Race and mental health diagnosis are risk factors for highly active antiretroviral therapy failure in a military cohort despite equal access to care. J Acquir Immune Defic Syndr 2007;44:411-416.
31. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: A mathematical model. Lancet 2009;373: 48-57.
32. Weinstock HS, Zaidi I, Heneine W, et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1- infected persons in 10 US cities. J Infect Dis 2004;189:2174-2180.
33. Pillay D, Bhaskaran K, Jurriaans S, et al. The impact of transmitted drug resistance on the natural history of HIV infection and response to first-line therapy. AIDS 2006; 20:21-28.
34. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
35. Sullivan P, Kayitenkore K, Chomba E, et al. Reduction of HIV Transmission Risk and High Risk Sex while Prescribed ART: Results from Discordant Couples in Rwanda and Zambia. Paper presented at: 16th Conference on Retroviruses and Opportunistic Infections, 2009; Montreal, Canada.